KR101418619B1 - 단백질 키나아제 억제제로서 유용한 피라졸로(1,5-ａ)(1,3,5)트리아진 및 피라졸로(1,5-ａ)피리미딘 유도체 - Google Patents

단백질 키나아제 억제제로서 유용한 피라졸로(1,5-ａ)(1,3,5)트리아진 및 피라졸로(1,5-ａ)피리미딘 유도체 Download PDF

Info

Publication number
KR101418619B1
KR101418619B1 KR1020097005501A KR20097005501A KR101418619B1 KR 101418619 B1 KR101418619 B1 KR 101418619B1 KR 1020097005501 A KR1020097005501 A KR 1020097005501A KR 20097005501 A KR20097005501 A KR 20097005501A KR 101418619 B1 KR101418619 B1 KR 101418619B1
Authority
KR
South Korea
Prior art keywords
amino
phenyl
pyrazolo
diaza
triazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097005501A
Other languages
English (en)
Korean (ko)
Other versions
KR20090083889A (ko
Inventor
샤오송 추
제 니에
카린 엘. 페레타
필립 유진 에릭손
Original Assignee
폴라리스 그룹
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 폴라리스 그룹 filed Critical 폴라리스 그룹
Publication of KR20090083889A publication Critical patent/KR20090083889A/ko
Application granted granted Critical
Publication of KR101418619B1 publication Critical patent/KR101418619B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020097005501A 2006-09-18 2007-09-18 단백질 키나아제 억제제로서 유용한 피라졸로(1,5-ａ)(1,3,5)트리아진 및 피라졸로(1,5-ａ)피리미딘 유도체 Expired - Fee Related KR101418619B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84531406P 2006-09-18 2006-09-18
US60/845,314 2006-09-18
US11/856,476 US7517882B2 (en) 2006-09-18 2007-09-17 Protein kinase inhibitors
US11/856,476 2007-09-17
PCT/US2007/020231 WO2008036277A1 (en) 2006-09-18 2007-09-18 Pyraz0l0(l,5-a) (1, 3, 5) triazine and pyrazolo (1, 5-a) pyrimidine derivatives useful as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
KR20090083889A KR20090083889A (ko) 2009-08-04
KR101418619B1 true KR101418619B1 (ko) 2014-07-14

Family

ID=39052753

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097005501A Expired - Fee Related KR101418619B1 (ko) 2006-09-18 2007-09-18 단백질 키나아제 억제제로서 유용한 피라졸로(1,5-ａ)(1,3,5)트리아진 및 피라졸로(1,5-ａ)피리미딘 유도체

Country Status (11)

Country Link
US (2) US7517882B2 (enExample)
EP (1) EP2064214B1 (enExample)
JP (1) JP5232786B2 (enExample)
KR (1) KR101418619B1 (enExample)
CN (1) CN101522683B (enExample)
AU (1) AU2007297675B2 (enExample)
BR (1) BRPI0718459A2 (enExample)
CA (1) CA2663791C (enExample)
ES (1) ES2400450T3 (enExample)
TW (1) TWI472530B (enExample)
WO (1) WO2008036277A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
WO2009126514A1 (en) * 2008-04-07 2009-10-15 Irm Llc Compounds and compositions as kinase inhibitors
JP6046728B2 (ja) * 2011-09-30 2016-12-21 オンコデザイン エス．ア． 大環状ｆｌｔ３キナーゼ阻害剤
BR112015022650A8 (pt) * 2013-03-15 2018-01-23 Oncodesign Sa inibidores de quinase induzível por sal macrocíclico.
CN103570728B (zh) * 2013-11-12 2015-12-30 山东大学 一种取代吡唑并[1,5-a]嘧啶类衍生物及其制备方法与应用
EP3268000B1 (en) * 2015-03-09 2021-08-04 Aurigene Discovery Technologies Limited Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
EP3490564A4 (en) * 2016-07-28 2020-02-26 Turning Point Therapeutics, Inc. MACRO CYCLE Kinase Inhibitors
FI3870579T3 (fi) 2018-10-22 2025-01-02 Alumis Inc Tyk2-inhibiittoreita ja niiden käyttöjä
CN113811534B (zh) * 2019-03-11 2024-10-29 阿鲁米斯公司 Tyk2抑制剂和其用途
BR112021019070A2 (pt) * 2019-03-26 2022-02-15 Ventyx Biosciences Inc Ligantes de pseudoquinase tyk2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004048384A1 (en) 2002-11-27 2004-06-10 Nad Ag N,n-bridged, nitrogen-substituted carbacyclic indolocarbazoles as protein kinase inhibitors
WO2004104007A1 (en) 2003-05-22 2004-12-02 Pharmacia Italia S.P.A. Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1752457B1 (en) 2004-06-02 2014-03-19 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004048384A1 (en) 2002-11-27 2004-06-10 Nad Ag N,n-bridged, nitrogen-substituted carbacyclic indolocarbazoles as protein kinase inhibitors
WO2004104007A1 (en) 2003-05-22 2004-12-02 Pharmacia Italia S.P.A. Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors

Also Published As

Publication number Publication date
KR20090083889A (ko) 2009-08-04
WO2008036277A1 (en) 2008-03-27
TW200837065A (en) 2008-09-16
US20080070893A1 (en) 2008-03-20
CN101522683A (zh) 2009-09-02
HK1135688A1 (en) 2010-06-11
JP2010503690A (ja) 2010-02-04
ES2400450T3 (es) 2013-04-10
US20090247501A1 (en) 2009-10-01
EP2064214A1 (en) 2009-06-03
CA2663791A1 (en) 2008-03-27
AU2007297675A1 (en) 2008-03-27
CN101522683B (zh) 2013-02-27
TWI472530B (zh) 2015-02-11
JP5232786B2 (ja) 2013-07-10
CA2663791C (en) 2015-11-03
EP2064214B1 (en) 2013-01-30
US7517882B2 (en) 2009-04-14
BRPI0718459A2 (pt) 2013-12-03
AU2007297675B2 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
KR101418619B1 (ko) 단백질 키나아제 억제제로서 유용한 피라졸로(1,5-ａ)(1,3,5)트리아진 및 피라졸로(1,5-ａ)피리미딘 유도체
AU2007316417B2 (en) Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
EP2497773B1 (en) Process for preparing a 5H-pyrimido[5,4-d][2]benzazepine
US20100210646A1 (en) 2-morpholin-4-yl-pyrimidines as pi3k inhibitors
CA2494127A1 (en) Pyrimido compounds having antiproliferative activity
HU221507B (en) Pyrazolo-pyrimidine derivatives, pharmaceutical compositions containing them as active agents process for the preparation thereof
EP3205650A1 (en) Egfr inhibitor, and preparation and application thereof
EP2123654A1 (en) Pyrazolopyrimidine compound
CA2706018A1 (en) 1, 5-dihydro-pyrazolo [3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
MX2013006443A (es) Compuesto de [1,2,4]triazolo[4,3-b][1,2,4]triacina, metodo de preparacion y uso del mismo.
KR20120125226A (ko) 타이로신 키나제 억제제로서 유용한 4－（치환된 아닐리노）－퀴나졸린 유도체
EP3998254A1 (en) 2-aminopyrimidine compound and application thereof
Liang et al. Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors
Zhang et al. Discovery of new BTK inhibitors with B cell suppression activity bearing a 4, 6-substituted thieno [3, 2-d] pyrimidine scaffold
CN119285624B (zh) 一种含噻吩的嘧啶类化合物及其制备方法与在制备具有抗癌作用的药物中的应用
HK1135688B (en) Pyrazolo (1,5-a)(1,3,5) triazine and pyrazolo (1,5-a) pyrimidine derivatives useful as protein kinase inhibitors
Liu et al. Design and synthesis of pyrrole–5-(2, 6-dichlorobenzyl) sulfonylindolin-2-ones with C-3′ side chains as potent Met kinase inhibitors
Guillard et al. Synthesis and Biological Evaluations of New Pyrrolo (2, 3-b) pyrimidine as SDI Analogs
WO2025236004A1 (en) Stat6 inhibitors and uses thereof
BRPI0619955A2 (pt) derivados tricìclicos da lactama, sua produção e seus usos como agentes farmacêuticos
CN117736198A (zh) 大环含氮冠醚化合物及其作为蛋白激酶抑制剂的应用
Soleiman Synthesis of Pyrrolo [3, 4-d] Pyrimidine Thiono Derivatives via Aza Wittig Reaction
HK1175778B (en) Process for preparing a 5h-pyrimido[5,4-d][2]benzazepine
HK1230615B (en) Novel imidazolidine-2,4-dione derivatives
HK1187616A (en) [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170628

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180626

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20190705

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190705